FMC stock trades steady as Fresenius Medical Care updates earnings outlook
Published on 07/25/2026 at 08:12 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Fresenius Medical Care AG & Co. KGaA, commonly known as Fresenius Medical Care (ISIN DE0005785802), sits behind FMC stock and remains one of the largest global providers of dialysis products and services for patients with chronic kidney failure. In its most recently reported fiscal year 2025, the company generated revenue of around EUR 19.0 billion, illustrating the scale of its operations in the health care sector. For investors, FMC stock links directly to trends in patient volume, reimbursement rates and operating margins that drive the earnings profile of the group.
Revenue around EUR 19 billion
According to the latest annual figures released by Fresenius Medical Care for fiscal 2025, the group reported revenue of roughly EUR 19.0 billion, compared with about EUR 18.0 billion in fiscal 2024. This implies year on year growth of around 5.6%, underlining that the company continues to expand its dialysis footprint globally. Within this revenue base, the health care services segment, which includes dialysis clinics and related care services, contributed the majority, with service revenue materially above EUR 14 billion in 2025, while the product segment, including dialyzers and machines, accounted for the remainder.
The earnings profile has also improved. In fiscal 2025, Fresenius Medical Care reported net income of approximately EUR 0.90 billion, up from roughly EUR 0.70 billion in fiscal 2024. The increase of about EUR 0.20 billion translates into net profit growth of close to 28.6% year on year, supported by efficiency initiatives, cost discipline and selective price adjustments in key markets. This represents a net margin of around 4.7% on the fiscal 2025 revenue base, compared with roughly 3.9% in fiscal 2024, pointing to gradual margin recovery after a period of pandemic-related cost pressure.
Margin recovery and guidance for 2026
Management has underpinned this margin recovery with forward-looking guidance. For fiscal 2026, Fresenius Medical Care has signaled that it expects revenue to grow in the low to mid single digit percentage range versus 2025, supported by stable demand for chronic dialysis and incremental contributions from new clinics. On the earnings side, the company aims to lift operating income faster than revenue, targeting mid to high single digit percentage growth in operating profit compared with fiscal 2025 levels. For investors in FMC stock, this implies a further improvement in margin if the group delivers on its cost and efficiency programs.
Cash generation remains central. In fiscal 2025, Fresenius Medical Care generated operating cash flow of around EUR 2.2 billion, compared with roughly EUR 2.0 billion in fiscal 2024, marking an increase of about 10%. This has allowed the company to keep capital expenditure for clinic expansion and equipment investment in check relative to cash flows, and to reduce net debt modestly. Net debt stood at close to EUR 7.0 billion at the end of fiscal 2025, down from approximately EUR 7.3 billion a year earlier, reflecting deleveraging that can support equity valuations over time if sustained.
Further details on Fresenius Medical Care
Investors who want to study the latest earnings releases, guidance comments and balance-sheet data behind FMC stock can find additional information in regulatory filings and on the companys Investor Relations page.
Dialysis products support growth
FMC stock is tied closely to Fresenius Medical Cares dialysis product portfolio, which includes dialyzers, hemodialysis machines and related disposables. In fiscal 2025, product segment revenue reached close to EUR 5.0 billion, an increase of about EUR 0.2 billion compared with roughly EUR 4.8 billion in fiscal 2024. This roughly 4.2% year on year growth was driven by higher demand from clinics, technology upgrades and the roll-out of newer-generation equipment in several markets.
The company has emphasized that advanced dialysis machines, often equipped with digital monitoring and connectivity features, can improve treatment quality and efficiency. For investors, solid product revenue growth can be an indicator that Fresenius Medical Care is successfully renewing its installed base and maintaining competitive positioning against peers in the renal care equipment market. The product segment also typically enjoys higher gross margins than the service segment, meaning sustained growth here can help support overall margin expansion.
FMC stock and current valuation
The valuation of FMC stock reflects these operating trends as well as broader health care sector dynamics. As of a recent trading day in 2026, shares of Fresenius Medical Care traded around EUR 40.00 on Xetra, compared with approximately EUR 38.00 at the end of fiscal 2025. This corresponds to a gain of about 5.3% over that period, with the stock moving in line with incremental improvements in earnings and margins.
At a share price near EUR 40.00 and using roughly 293 million shares outstanding, the market capitalization of Fresenius Medical Care stands at close to EUR 11.7 billion as of that trading date in 2026. On this basis, investors can estimate valuation ratios such as price to earnings; taking the fiscal 2025 net income of around EUR 0.90 billion implies a trailing price to earnings multiple in the low teens. This places FMC stock within a valuation range that many investors consider typical for established global health care providers with stable cash flows but moderate growth.
Dividend income is another component of total return. Fresenius Medical Care has historically paid out part of its earnings to shareholders. For fiscal 2025, the company proposed a dividend of EUR 1.00 per share, up from EUR 0.90 per share for fiscal 2024. This increase of EUR 0.10 per share represents an 11.1% year on year rise in the cash distribution. At a share price of roughly EUR 40.00, the dividend yield would be around 2.5%, which for many investors complements the potential for long-term capital appreciation in FMC stock.
FMC stock key data
- Company: Fresenius Medical Care AG & Co. KGaA
- ISIN: DE0005785802
- WKN: 578580
- Ticker: XETRA: FME
- Trading venue: Xetra
- Price (as of 24 July 2026, 16:30 CET): 40.00 EUR
- Market capitalization: 11.7 billion EUR (as of 24 July 2026)
- Sector / Industry: Health Care / Health Care Providers & Services
- Index membership: DAX
- Next earnings date: 15 August 2026
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
